hENT2 is the human nucleoside transporter for which most splice variants have been described to date, in contrast to hENT1 for which no variants have been reported yet. In this dissertation, we have identified 3 novel splice variants of hENT2 which encode 2 novel nuclear isoforms of this transporter protein. As we demonstrated, these variants appear to be functional and ubiquitously expressed among cell lines and tissues, although the pattern of expression levels may vary depending on the growth conditions and the cellular needs. The physiological role of these novel nuclear variants of hENT2 still remains unclear, since there is no evidence of the presence of the nucleoside salvage pathway inside the nucleus. Therefore, the presence of nucleoside transporters at the nuclear membrane might not have any relevant meaning. Nonetheless, based on the protein-protein interactions obtained from the screening with MYTH technique, other functional implications are coming up. These nuclear variants of hENT2 could be involved in alternative splicing regulation, since they appeared to interact with several splicing factors. As we proved, hENT2 splicing patterns vary depending upon growth conditions, suggesting the existence of a regulation (or even a self-regulation) mechanism of the splicing phenomenon. Several proteins have been previously described as self-regulators of alternative splicing (Sureau et al. 2001; Sun et al. 2010; de Morree et al. 2012). In this dissertation we propose the hypothesis of HNP32 and HNP36 proteins, localized at the nuclear membrane, interacting with splice regulation factors and modulating their availability to bind pre-mRNA, thus determining the splice sites recognized by the spliceosome. In such a way, hENT2 itself would regulate the ratio between the wt isoform and the nuclear variants to adapt itself to the cellular situation. According to our in vitro phosphorylation assays, hENT2 could be phosphorylated by CKII inside the cell. CKII is a kinase that appears to be unregulated because it is constitutively active. Therefore, it has been suggested that changes in the phosphorylation status of CKII substrates would depend on regulated dephosphorylation (Pinna 1990). Considering the putative interaction between hENT2 and PP1, we propose a possible regulation of hENT2 by phosphorylation, where the transporter would be phosphorylated by default and regulation would come by dephosphorylation via PP1. Actually, considering our biotinylation results where we found a double band at 54 KDa, the supposed phosphorylated protein would remain intracellular while the supposed non phosphorylated protein would be active at the plasma membrane. Although we could not demonstrate a direct in vitro phosphorylation of hENT2 by PKC, this kinase appears to be involved in hENT2 trafficking regulation. Activation of PKC promotes hENT2 trafficking to the plasma membrane although it does not necessarily entails an increase of hENT2-related transport activity. Actually, the clear consequence of the hENT2 translocation to the plasma membrane is a significant decrease on hENT1 activity. We propose the theory of a dual population of hENT2 proteins at the plasma membrane. One non-phosphorylated hENT2 isoform of 54 KDa could be related with transport activity, while another isoform of 45 KDa would not be active as a transporter, despite being present at the plasma membrane. Similarly, two different kinds of regulation by phosphorylation would affect hENT2 function, either regulating its trafficking to the plasma membrane via PKC, or activating its function as a nucleoside transporter via PP1. These two putative pathways of regulation would not necessarily be independent of each other. Finally, our transcriptomic analysis of gastro-hepatic cell lines allowed us to place ENT2 within a global gene network involved in cell proliferation and survival. PKC appeared to be a possible central point of regulation of that network, coordinating a global response of the cell to the growth and environmental conditions. In addition, part of that novel network, including hENT2, could be involved in response to paclitaxel treatment. As we understand, a positive response to the therapy would not be determined by the hENT2 role as a transporter, but by the context of this network connecting several genes involved in proliferation and cell survival.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados